JNJ 8-K Current Reports
JOHNSON & JOHNSON - 320 current reports
JOHNSON & JOHNSON 8-K Report, Shareholder Vote Results (Apr 28, 2026)
Johnson & Johnson (JNJ) filed an 8-K on April 28, 2026, detailing the outcomes of its 2026 Annual Meeting of Shareholders held on April 23, 2026. The report indicates strong shareholder support for the company's slate of director nominees and its executive compensation practices. All 12 director nominees were elected to the Board of Directors, and the executive compensation, as described in the proxy statement, was approved on an advisory basis. Additionally, shareholders ratified the appointment of PricewaterhouseCoopers LLP as the company's independent registered public accounting firm for fiscal year 2026, reflecting confidence in the company's governance and financial oversight. Notably, a shareholder proposal seeking to adopt a policy requiring an independent board chair was not approved. This outcome suggests that the current board structure and leadership model are favored by the majority of JNJ's shareholders. The detailed voting results for each item are provided in the filing, offering transparency into shareholder sentiment on key governance matters.
JOHNSON & JOHNSON 8-K Report, Financial Results (Apr 14, 2026)
Johnson & Johnson (JNJ) has filed an 8-K report on April 14, 2026, announcing key financial updates for the first quarter ended March 29, 2026. The report includes details on the company's sales and earnings, as presented in an attached press release (Exhibit 99.1). While specific financial figures for sales and earnings are not detailed within the 8-K itself, investors are directed to the press release for this information. Additionally, the company's Board of Directors has declared a significant increase in its quarterly dividend, marking the 64th consecutive year of dividend growth. This demonstrates a continued commitment to returning value to shareholders and reflects confidence in the company's financial health and future prospects. The dividend increase and its payout details are important considerations for income-focused investors.
JOHNSON & JOHNSON 8-K Report, Financial Results (Jan 21, 2026)
Johnson & Johnson (JNJ) has filed an 8-K report on January 21, 2026, to announce its financial results for the fourth quarter and full year ended December 28, 2025. The filing primarily directs investors to a press release (Exhibit 99.1) and supplementary data (Exhibit 99.2) for detailed sales and earnings information. While the 8-K itself does not contain the specific figures, these attached exhibits are the primary source for understanding the company's performance during the reported periods, including key financial metrics and operational achievements.
JOHNSON & JOHNSON 8-K Report, Financial Results (Oct 14, 2025)
Johnson & Johnson has filed an 8-K report highlighting key developments from its third quarter of 2025. The company announced its sales and earnings results for the quarter ended September 28, 2025, providing investors with updated financial performance data. This report also contains a significant strategic announcement regarding the company's intention to separate its Orthopaedics business. This separation could reshape JNJ's business portfolio and potentially unlock value for shareholders by allowing each segment to focus on its distinct growth opportunities.
JOHNSON & JOHNSON 8-K Report, Executive Changes (Sep 9, 2025)
Johnson & Johnson (JNJ) has announced a significant addition to its Board of Directors with the election of John Morikis, effective September 8, 2025. Mr. Morikis brings extensive leadership experience, having served as Executive Chairman, President, and CEO of The Sherwin-Williams Company from 2016 to 2024, with a career spanning nearly forty years at the company. His appointment is expected to enhance the Board's expertise, particularly given his significant tenure in executive roles. Mr. Morikis has been assigned to key committees, including the Audit Committee and the Compensation & Benefits Committee, indicating his immediate and strategic role within the company's governance. His compensation as a non-employee director will align with the standard practices outlined in JNJ's 2025 Proxy Statement.
JOHNSON & JOHNSON 8-K Report, Financial Results (Jul 16, 2025)
Johnson & Johnson (JNJ) has filed an 8-K report detailing its second-quarter financial results for the period ended June 29, 2025. The filing primarily references a press release and supplementary financial data, providing investors with key operational and financial performance metrics for the recently concluded quarter. This report is crucial for understanding the company's recent sales trends and earnings, which are vital indicators of its ongoing business health and strategic execution within its diverse segments, including pharmaceuticals, medical devices, and consumer health. Investors should review the attached exhibits for a comprehensive understanding of the company's performance against expectations and its trajectory for the remainder of the fiscal year. The provided documentation includes the press release announcing Q2 2025 results and unaudited comparative supplementary sales data along with condensed consolidated statements of earnings. These materials are essential for evaluating Johnson & Johnson's financial condition and operational results, allowing for comparisons to prior periods and potentially to industry benchmarks. The market will be closely watching these figures to assess the impact of various economic factors, competitive pressures, and the company's strategic initiatives on its bottom line and revenue generation.
JOHNSON & JOHNSON 8-K Report, Executive Changes (Jun 10, 2025)
Johnson & Johnson (JNJ) has announced a significant addition to its Board of Directors with the election of Daniel Pinto, effective July 1, 2025. Mr. Pinto, currently President of JPMorgan Chase and set to become Vice Chairman, brings extensive financial expertise to the board. His appointment to both the Audit Committee and the Compensation & Benefits Committee is noteworthy, suggesting a focus on financial oversight and executive compensation strategies. This appointment comes with the disclosure of a prior business relationship between JNJ and JPMorgan Chase, with JNJ paying approximately $39.2 million in fiscal year 2024 for various banking services. Investors should note that while Mr. Pinto's role at JPMorgan Chase involves services provided to JNJ, his director compensation will be in line with the Company's standard non-employee director compensation as outlined in its proxy statement. This move signals a potential strengthening of JNJ's governance and financial acumen.
JOHNSON & JOHNSON 8-K Report, Executive Changes (Apr 30, 2025)
Johnson & Johnson (JNJ) filed an 8-K on April 29, 2025, reporting on the company's 2025 Annual Meeting of Shareholders held on April 24, 2025. The report details the outcomes of various shareholder votes, including the election of all 11 director nominees and the advisory approval of executive compensation. Notably, the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025 was ratified. The filing also announced the upcoming retirement of board member D. Adamczyk, effective May 31, 2025, due to his decision to join Goldman Sachs as a Partner. This departure is stated to be for personal reasons and not a result of any disagreement with the company's management.
JOHNSON & JOHNSON 8-K Report, Financial Results (Apr 15, 2025)
Johnson & Johnson (JNJ) has filed a Form 8-K on April 15, 2025, reporting key financial updates and shareholder returns. The company announced its first-quarter 2025 sales and earnings results, details of which are available in an accompanying press release. This provides investors with crucial performance metrics for the period ending March 30, 2025, enabling an assessment of the company's operational strength and market position. Furthermore, JNJ's Board of Directors has approved a 4.8% increase in its quarterly dividend, raising it from $1.24 to $1.30 per share. This marks the 63rd consecutive year of dividend increases, underscoring the company's commitment to returning capital to shareholders and its financial stability. The annualized dividend now stands at $5.20 per share, reflecting sustained dividend growth.
JOHNSON & JOHNSON 8-K Report, Regulation FD Disclosure (Apr 3, 2025)
Johnson & Johnson (JNJ) has filed an 8-K report on April 2, 2025, disclosing a significant development regarding its subsidiary Red River Talc LLC. The U.S. Bankruptcy Court for the Southern District of Texas has denied the confirmation of Red River Talc LLC's proposed prepackaged bankruptcy plan. This decision carries substantial financial implications for the company.
JOHNSON & JOHNSON 8-K Report, Corporate Update (Feb 26, 2025)
Johnson & Johnson (JNJ) has announced the completion of a significant public offering of senior unsecured notes denominated in Euros. This offering, which closed on February 25, 2025, involved five tranches with varying maturities and coupon rates, totaling €4.0 billion. The notes were issued under the company's existing shelf registration statement and were underwritten by a syndicate of major financial institutions. This move suggests JNJ is actively managing its capital structure and potentially raising funds for general corporate purposes, such as financing operations, acquisitions, or repaying existing debt.
JOHNSON & JOHNSON 8-K Report, Corporate Update (Feb 20, 2025)
Johnson & Johnson (JNJ) announced the completion of a significant public offering of debt securities on February 20, 2025. The company successfully issued a total of $5.25 billion in notes across various maturities ranging from 2027 to 2035. This capital raise includes $750 million in 4.500% Notes due 2027, $750 million in 4.550% Notes due 2028, $1 billion in 4.700% Notes due 2030, $1.25 billion in 4.850% Notes due 2032, and $1.25 billion in 5.000% Notes due 2035. The offering was conducted under the company's existing shelf registration statement.
JOHNSON & JOHNSON 8-K/A Report, Exhibit Filing (Jan 22, 2025)
Johnson & Johnson (JNJ) filed an 8-K/A amendment on January 22, 2025, primarily to furnish a press release dated January 22, 2025. This press release pertains to the period ended December 29, 2024, suggesting it contains updated financial or operational information relevant to the company's recent performance. Investors should review this press release for details on the company's performance and any potential implications for future outlook. While the filing itself is an amendment and does not introduce new material events, the attached press release is crucial for understanding JNJ's latest business developments and financial standing as of the fourth quarter of 2024. Investors are encouraged to examine the content of the press release for any announcements regarding sales, earnings, product pipelines, or strategic shifts that could impact the company's valuation and investment thesis.
JOHNSON & JOHNSON 8-K Report, Financial Results (Jan 22, 2025)
Johnson & Johnson (JNJ) has filed an 8-K report on January 21, 2025, detailing its financial performance for the fourth quarter and full year ended December 29, 2024. The core of this filing is the press release (Exhibit 99.1) and supplementary financial data (Exhibit 99.2) which provide investors with key sales and earnings figures. While the filing itself does not contain granular operational details or forward-looking guidance, it serves as the official vehicle for disseminating the company's recently concluded fiscal period results.
JOHNSON & JOHNSON 8-K Report, Financial Results (Oct 15, 2024)
Johnson & Johnson (JNJ) filed an 8-K on October 15, 2024, to report its third-quarter 2024 financial results, which concluded on September 29, 2024. The filing primarily directs investors to the attached press release (Exhibit 99.1) for detailed sales and earnings information. While the 8-K itself does not contain the specific figures, it serves as the official notification and repository for the company's performance disclosure for the quarter.
JOHNSON & JOHNSON 8-K Report, Regulation FD Disclosure (Sep 20, 2024)
Johnson & Johnson (JNJ) announced through its subsidiary Red River Talc LLC, the filing of a voluntary prepackaged Chapter 11 bankruptcy case on September 20, 2024. This strategic move is designed to comprehensively and permanently resolve all existing and future ovarian cancer claims stemming from cosmetic talc litigation in the United States. The filing was supported by a significant majority (approximately 83%) of current claimants for the proposed bankruptcy plan, indicating broad consensus among affected parties.
JOHNSON & JOHNSON 8-K Report, Executive Changes (Sep 10, 2024)
Johnson & Johnson (JNJ) filed an 8-K on September 10, 2024, primarily to announce the retirement of Director D. S. Davis. Mr. Davis stepped down from the Board of Directors after successfully transitioning his responsibilities as Chair of the Audit Committee to D. Adamczyk. The company emphasized that Mr. Davis's retirement is for personal reasons and is not indicative of any disagreements with the company's management or its operational, policy, or practice matters. This transition appears to be a planned succession within the Board's committee leadership.
JOHNSON & JOHNSON 8-K Report, Executive Changes (Aug 26, 2024)
Johnson & Johnson (JNJ) has announced a significant leadership transition via an 8-K filing on August 26, 2024. Peter M. Fasolo, the Executive Vice President and Chief Human Resources Officer (CHRO), has elected to retire. Mr. Fasolo will step down from his executive role and the Executive Committee effective October 1, 2024, and will officially depart the company by the end of the calendar year. This change marks the end of Mr. Fasolo's tenure in a key strategic position within the company's leadership structure. While the filing primarily reports on this executive departure, it is important for investors to note that a formal press release detailing this event has been issued and is included as an exhibit. Investors should monitor future filings for information regarding the appointment of a successor to Mr. Fasolo and any potential impact this leadership change may have on the company's human capital strategy, talent management, and overall organizational development.
JOHNSON & JOHNSON 8-K Report, Financial Results (Jul 17, 2024)
Johnson & Johnson (JNJ) filed an 8-K on July 17, 2024, primarily to disclose its financial results for the second quarter ended June 30, 2024. The filing includes a press release and supplementary sales data, offering investors a look into the company's operational performance and financial condition during the period. Investors should review the attached exhibits for detailed sales figures and earnings statements to understand the company's revenue generation and profitability trends.
JOHNSON & JOHNSON 8-K Report, Corporate Update (May 20, 2024)
Johnson & Johnson (JNJ) announced the completion of significant public offerings for both U.S. Dollar and Euro denominated notes on May 20, 2024. This filing details the issuance of approximately $4.0 billion in U.S. Dollar notes across various maturities (2029, 2031, 2034, and 2054) with coupon rates ranging from 4.800% to 5.250%. Additionally, JNJ issued approximately €2.5 billion in Euro notes with maturities in 2032, 2036, and 2044, carrying coupon rates from 3.200% to 3.550%. These offerings, conducted under the company's existing Form S-3 registration statement, represent a strategic move to raise capital. Investors should note that this transaction primarily relates to debt financing and does not involve equity issuance or significant operational updates. The filings also include details of the underwriting agreements with major financial institutions like J.P. Morgan, BofA Securities, and Citigroup.
JOHNSON & JOHNSON 8-K Report, Corporate Update (May 17, 2024)
Johnson & Johnson (JNJ) has finalized its divestiture of its remaining stake in its former Consumer Health business, now operating as Kenvue Inc. The company announced on May 17, 2024, that it completed a Debt-for-Equity Exchange. In this transaction, JNJ exchanged its remaining 182.3 million shares of Kenvue Common Stock for $3.6 billion aggregate principal amount of commercial paper that it had issued on May 15, 2024. This exchange effectively settles the commercial paper and marks the complete exit of Johnson & Johnson from its ownership of Kenvue. This strategic move concludes Johnson & Johnson's long-planned separation of its consumer health division. The initial separation began with Kenvue's IPO in May 2023, followed by a significant exchange offer in August 2023 that reduced JNJ's stake substantially. The final exchange of shares for debt removes any lingering ownership ties and allows Johnson & Johnson to fully focus on its pharmaceutical and medtech segments. Investors should view this as a significant step in JNJ's strategic realignment.
JOHNSON & JOHNSON 8-K Report, Financial Results (May 1, 2024)
Johnson & Johnson (JNJ) filed an 8-K on May 1, 2024, primarily to disclose a significant development regarding its talc litigation. The company announced a proposed Plan of Reorganization to comprehensively resolve all current and future ovarian cancer claims in the United States, excluding certain specific claims. This resolution is contingent upon the payment of approximately $6.475 billion (present value) over 25 years, with a nominal value of roughly $8.4 billion. This proposed settlement has a material impact on JNJ's first-quarter 2024 financial results. The company recorded an incremental charge of approximately $2.7 billion, bringing the total reserve for these liabilities to a present value of approximately $11 billion. Consequently, reported GAAP net earnings for Q1 2024 have been reduced from $5.4 billion to $3.3 billion, and reported GAAP EPS has been lowered from $2.20 to $1.34. Importantly, these adjustments do not affect Adjusted Earnings, Adjusted EPS, or Adjusted Operational EPS, which remain unchanged.
JOHNSON & JOHNSON 8-K Report, Bylaw Amendment (Apr 29, 2024)
Johnson & Johnson (JNJ) filed an 8-K on April 29, 2024, detailing key governance and shareholder meeting outcomes from their 2024 Annual Meeting held on April 25, 2024. The most significant corporate action was the adoption of amended and restated by-laws, which introduce updated procedures for shareholder actions, including calling special meetings and submitting director nominations or proposals. These changes aim to align with current regulatory standards, such as universal proxy rules, and clarify existing corporate governance practices. Furthermore, the filing provides the final voting results from the Annual Meeting. Shareholders overwhelmingly elected all 13 director nominees, approved executive compensation on an advisory basis, and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2024. Notably, a shareholder proposal requesting a report on gender-based compensation gaps and associated risks was not approved.
JOHNSON & JOHNSON 8-K/A Report, Exhibit Filing (Apr 16, 2024)
Johnson & Johnson (JNJ) filed an 8-K/A amendment on April 16, 2024, primarily to provide an updated exhibit. This filing includes a press release dated April 16, 2024, which likely contains financial results for the period ended March 31, 2024. Investors should refer to this press release for the latest updates on the company's performance, including key financial metrics, segment results, and any forward-looking guidance that may have been provided. The nature of this filing as an amendment suggests that the original 8-K filing may have been incomplete or that additional information, specifically the press release, was required. Investors should carefully review the press release for details regarding JNJ's first-quarter 2024 performance, as this is the primary informational content being added via this amendment.
JOHNSON & JOHNSON 8-K Report, Financial Results (Apr 16, 2024)
Johnson & Johnson (JNJ) filed an 8-K on April 16, 2024, to announce its first-quarter 2024 financial results and a significant increase in its quarterly dividend. The company reported its sales and earnings for the quarter ended March 31, 2024, as detailed in an attached press release (Exhibit 99.1). While specific financial figures are not detailed within the 8-K text itself, investors can access the comprehensive earnings report via the referenced exhibit for in-depth analysis of performance across its segments. Furthermore, the filing highlights a notable increase in shareholder returns. The Board of Directors approved a 4.2% hike in the quarterly dividend, raising it from $1.19 to $1.24 per share. This marks the 62nd consecutive year of dividend increases, underscoring JNJ's commitment to returning capital to shareholders and its consistent financial strength. The new annual dividend rate will be $4.96 per share.
JOHNSON & JOHNSON 8-K Report, Financial Results (Jan 23, 2024)
Johnson & Johnson (JNJ) filed an 8-K on January 23, 2024, to announce its fourth quarter and full-year 2023 financial results. The filing primarily directs investors to a press release (Exhibit 99.1) and supplementary financial data (Exhibit 99.2) containing detailed sales and earnings information for the periods ending December 31, 2023. Investors should review these attached documents for a comprehensive understanding of the company's performance, including revenue generation and profitability across its various segments.
JOHNSON & JOHNSON 8-K Report, Executive Changes (Dec 5, 2023)
Johnson & Johnson announced a significant addition to its Board of Directors with the election of Eugene A. Woods, MBA, MHA, effective November 30, 2023. Mr. Woods brings valuable experience as the Chief Executive Officer of Advocate Health, a major healthcare system. This appointment is noteworthy as Advocate Health is a customer of Johnson & Johnson, purchasing medical technologies and pharmaceuticals in the ordinary course of business. While this creates a related-party transaction, the company has disclosed the approximate financial scale of these dealings, with Advocate Health spending around $175 million on JNJ products in fiscal year 2022 and JNJ spending less than $1 million on clinical trials with Advocate Health. Investors should view this appointment as potentially strengthening the Board's understanding of hospital operations and customer perspectives. The disclosure of the customer relationship is standard practice and provides transparency. Mr. Woods will receive standard non-employee director compensation as outlined in the company's proxy statement. The filing also includes the press release announcing this appointment as an exhibit.
JOHNSON & JOHNSON 8-K Report, Corporate Update (Dec 5, 2023)
Johnson & Johnson (JNJ) announced on December 5, 2023, that it will host an Enterprise Business Review meeting with the investment community. This event is designed to provide a comprehensive overview of the company's strategic direction, showcase its robust pipelines within both its Innovative Medicine and MedTech segments, and outline its long-term financial projections. Investors should pay close attention to the strategic updates and pipeline progress as these will be key drivers of future growth and profitability. The company has attached a press release regarding this Enterprise Business Review as an exhibit to its 8-K filing. Additional materials and webcast registration information are also made available, signaling the company's intent to ensure broad investor access to this significant strategic update. The focus on both segments suggests a balanced approach to growth, and the long-term financial outlook will be critical for assessing the company's future value proposition.
JOHNSON & JOHNSON 8-K Report, Corporate Update (Nov 30, 2023)
Johnson & Johnson (JNJ) announced on November 30, 2023, the acquisition of Laminar, Inc. This strategic move, categorized as an asset acquisition, will result in an in-process research and development charge. Consequently, JNJ is revising its Adjusted Earnings Per Share (EPS) guidance for the fiscal year 2023. The company now anticipates Adjusted EPS to be between $9.85 to $9.91 on an operational basis and $9.90 to $9.96 on a reported basis. This reflects a reduction of approximately $0.17 from previously issued guidance due to the acquisition-related charge. Furthermore, the acquisition is projected to have a negative EPS impact of approximately $0.15 in fiscal year 2024.
JOHNSON & JOHNSON 8-K Report, Executive Changes (Nov 27, 2023)
Johnson & Johnson (JNJ) announced the adoption of a new Deferred Compensation Plan (the "Plan") effective November 21, 2023. This unfunded, nonqualified plan allows eligible management and highly compensated employees, including named executive officers, to defer a portion of their pre-tax base salary and annual cash performance bonuses. Participants can defer up to 50% of their base salary and 100% of their annual cash bonus for the following year. All amounts deferred, along with any investment gains or losses, are immediately vested with the employee. This plan replaces the previous Executive Income Deferral Plan (EIDP) for future deferrals, while existing EIDP balances will transition to the new plan's terms regarding payment timing and investment options.
JOHNSON & JOHNSON 8-K Report, Executive Changes (Oct 23, 2023)
Johnson & Johnson (JNJ) announced a significant leadership change within its MedTech segment via an 8-K filing dated October 23, 2023. Ashley McEvoy, Executive Vice President and Worldwide Chair of MedTech, has resigned from her position, effective October 20, 2023. She will remain with the company until the first quarter of 2024 to facilitate a transition period. This departure marks the end of her tenure on the Executive Committee and represents a notable change in leadership for a key segment of the company's operations.
JOHNSON & JOHNSON 8-K Report, Financial Results (Oct 17, 2023)
Johnson & Johnson (JNJ) filed an 8-K on October 17, 2023, to announce its third-quarter financial results for the period ended October 1, 2023. The filing primarily references a press release (Exhibit 99.1) and supplementary financial data (Exhibit 99.2) detailing sales and earnings for the quarter and the year-to-date period. Investors should review the referenced exhibits for specific performance metrics, including revenue growth across segments and profitability. This report serves as the official notification of the company's latest financial performance, setting the stage for investor analysis and potential market reactions.
JOHNSON & JOHNSON 8-K Report, Financial Results (Aug 30, 2023)
Johnson & Johnson (JNJ) has filed an 8-K report detailing the financial implications and updated guidance following the completion of its Kenvue Inc. separation. The company has finalized an exchange offer, effectively divesting its stake in Kenvue. This strategic move is expected to reshape JNJ's financial profile, allowing it to focus more intently on its core pharmaceutical and medical technology businesses. The press release accompanying this filing provides crucial updated financial figures and revised 2023 guidance. Investors should pay close attention to these adjustments, as they reflect the impact of the Kenvue Separation on JNJ's revenue streams, profitability, and overall financial outlook. The updated data will be essential for assessing the company's performance and future prospects as a more streamlined entity.
JOHNSON & JOHNSON 8-K Report, Acquisition Completed (Aug 25, 2023)
Johnson & Johnson (JNJ) has completed a significant strategic maneuver by finalizing its split-off exchange offer for Kenvue Inc. common stock. This transaction involved shareholders tendering their JNJ shares in exchange for Kenvue shares, effectively reducing Johnson & Johnson's ownership stake in the consumer health company. This move is a key step in JNJ's previously announced strategy to fully separate from Kenvue, allowing Johnson & Johnson to sharpen its focus on its two core segments: MedTech and Pharmaceuticals. Investors should note that this reduction in Kenvue shares represents a divestiture of a former subsidiary, which could impact future revenue and earnings profiles as JNJ streamlines its business operations.
JOHNSON & JOHNSON 8-K Report, Temporary Suspension of Trading Under Employee Benefit Plans (Jul 28, 2023)
Johnson & Johnson (JNJ) has filed an 8-K report on July 28, 2023, to disclose a potential temporary trading suspension, commonly known as a "blackout period," for its directors and executive officers. This is in connection with the company's ongoing offer to exchange a significant portion of its Kenvue Inc. common stock for outstanding Johnson & Johnson shares. The blackout period is triggered if 50% or more of the participants in JNJ's employee benefit plans elect to tender their JNJ shares held within the company's stock fund as part of the Kenvue exchange offer. This is a regulatory requirement under Sarbanes-Oxley Act and Regulation BTR, aimed at restricting insider trading during certain corporate events that could affect employee benefit plans. If imposed, the blackout period is expected to commence around August 15, 2023, and last through the week of August 28, 2023, assuming the Kenvue exchange offer does not extend. During this time, JNJ's directors and officers will be restricted from buying or selling JNJ securities, with limited exemptions, though they will still have the opportunity to participate in the Kenvue exchange offer. Investors should note that this event primarily impacts insider trading and employee benefit plan participants, rather than the company's ongoing business operations or financial performance, but it signals a significant step in the Kenvue divestiture process.
JOHNSON & JOHNSON 8-K Report, Corporate Update (Jul 24, 2023)
Johnson & Johnson (JNJ) filed an 8-K on July 24, 2023, primarily to announce certain preliminary results for the period ended July 2, 2023. While the filing itself does not contain detailed financial statements, it incorporates by reference Exhibit 99.1, which presumably holds these preliminary results. Investors should refer to Exhibit 99.1 for specific figures related to the company's performance in the period. This type of filing typically precedes a more comprehensive earnings release and aims to provide timely updates on key performance indicators or significant developments.
JOHNSON & JOHNSON 8-K Report, Financial Results (Jul 20, 2023)
Johnson & Johnson (JNJ) filed an 8-K on July 20, 2023, primarily to announce its second-quarter 2023 financial results. The report includes details on sales and earnings for the quarter ended July 2, 2023, as presented in an attached press release (Exhibit 99.1). This filing is crucial for investors seeking to understand the company's recent performance and financial health. While the 8-K itself is brief and acts as a vehicle for the press release, the information contained within that release is critical. Investors should pay close attention to the reported sales figures, earnings per share, and any commentary on the performance of JNJ's key business segments, including Pharmaceuticals and MedTech. The supplementary sales data and condensed consolidated statement of earnings provide a more detailed financial picture for the quarter and year-to-date period.
JOHNSON & JOHNSON 8-K Report, Material Agreement (May 8, 2023)
Johnson & Johnson (JNJ) has reported the completion of Kenvue Inc.'s initial public offering (IPO) on May 8, 2023. Kenvue, previously a wholly-owned subsidiary, offered 198,734,444 shares at $22.00 per share, raising approximately $4,241 million in net proceeds. These proceeds will be paid to Johnson & Johnson as partial consideration for the consumer health business transferred to Kenvue. Following the IPO, Johnson & Johnson retains a significant stake, owning approximately 89.6% of Kenvue's outstanding common stock. As a result, Johnson & Johnson will continue to consolidate Kenvue's financial results. The company also entered into a comprehensive Separation Agreement with Kenvue, outlining key corporate actions, asset and liability allocation, and agreements related to Kenvue's relationship with Johnson & Johnson post-IPO, including potential future dispositions of Kenvue shares.
JOHNSON & JOHNSON 8-K Report, Executive Changes (May 1, 2023)
This 8-K filing from Johnson & Johnson reports on the outcomes of their 2023 Annual Meeting of Shareholders held on April 27, 2023. A key event detailed is the departure of Thibaut Mongon from his Executive Vice President role to fully assume his CEO position at Kenvue Inc., following Kenvue's initial public offering. This transition marks a significant step in the separation and independent operation of the consumer health business. Shareholders overwhelmingly supported the re-election of all 12 director nominees and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor. The company also received advisory approval for its executive compensation and the annual frequency of such advisory votes. However, two shareholder proposals, one requesting a Vaccine Pricing Report and another on the impact of extended patent exclusivities on product access, did not receive sufficient support for approval. This filing provides clarity on corporate governance matters and key leadership changes impacting the company's structure.
JOHNSON & JOHNSON 8-K Report, Financial Results (Apr 18, 2023)
Johnson & Johnson (JNJ) filed an 8-K on April 18, 2023, primarily to report its first-quarter 2023 financial results and announce a dividend increase. The company's performance for the quarter ended April 2, 2023, was detailed in a press release (Exhibit 99.1), which is a key piece of information for investors assessing the company's operational health and profitability. The filing also includes supplementary sales data and condensed consolidated statements of earnings for the quarter. In addition to financial results, JNJ announced a significant increase in its quarterly dividend. The Board of Directors approved a 5.3% hike in the quarterly dividend rate, raising it from $1.13 to $1.19 per share. This translates to an annualized dividend of $4.76 per share, up from $4.52. This dividend increase underscores the company's financial strength and its commitment to returning value to shareholders, a positive signal for income-focused investors.
JOHNSON & JOHNSON 8-K Report, Regulation FD Disclosure (Apr 4, 2023)
Johnson & Johnson (JNJ) announced on April 4, 2023, that its subsidiary, LTL Management LLC, has re-filed for Chapter 11 bankruptcy protection. This move is intended to facilitate a reorganization plan designed to address all present and future claims related to cosmetic talc litigation in North America. The company has committed to contributing up to $8.9 billion (present value) over 25 years, with a nominal value of approximately $12 billion, to settle these claims.
JOHNSON & JOHNSON 8-K Report, Executive Changes (Apr 3, 2023)
This 8-K filing from Johnson & Johnson (JNJ) primarily reports on the retirement of Director Ian E. L. Davis, effective March 31, 2023. The retirement was pre-announced in the company's March 15th proxy statement and is in line with the board's refreshment criteria, not due to any disagreements with management. While this event is a change in board composition, it does not appear to signal any operational issues or strategic shifts for the company.
JOHNSON & JOHNSON 8-K/A Report, Executive Changes (Feb 15, 2023)
Johnson & Johnson (JNJ) has announced the appointment of Dr. Paula A. Johnson, President of Wellesley College, to its Board of Directors. This appointment is effective immediately and signifies a strategic addition to the company's leadership. Dr. Johnson brings a wealth of experience from her role at a prominent educational institution, which may offer a fresh perspective on governance and strategic direction. Furthermore, Dr. Johnson will be joining the Board's Nominating & Corporate Governance Committee starting April 27, 2023. This committee plays a crucial role in identifying and recommending director candidates and overseeing corporate governance policies. Her involvement in this committee suggests an emphasis on strengthening the company's governance framework and ensuring a robust pipeline of qualified board members. Investors should note that as a non-employee director, her compensation will align with the company's standard director compensation practices, as detailed in the upcoming 2023 Proxy Statement.
JOHNSON & JOHNSON 8-K Report, Executive Changes (Feb 14, 2023)
Johnson & Johnson (JNJ) announced a significant addition to its Board of Directors with the appointment of Paula A. Johnson, Chairman and CEO of Honeywell. This move brings a seasoned executive with extensive leadership experience to JNJ's governance structure. Ms. Johnson's appointment is effective immediately, and she will also serve on the Board's Nominating & Corporate Governance Committee starting April 27, 2023. Her expertise is expected to contribute to the strategic direction and oversight of the company.
JOHNSON & JOHNSON 8-K Report, Financial Results (Jan 24, 2023)
Johnson & Johnson (JNJ) filed an 8-K on January 24, 2023, to report its fourth quarter and full-year financial results for the period ended January 1, 2023. The report primarily contains a press release and supplementary financial data, highlighting the company's operational and financial performance. Investors should review these documents for details on sales, earnings, and other key financial metrics that could impact the company's valuation and future outlook.
JOHNSON & JOHNSON 8-K Report, Material Agreement (Dec 22, 2022)
Johnson & Johnson (JNJ) has filed an 8-K detailing the completion of its acquisition of ABIOMED, Inc. The tender offer for ABIOMED shares concluded with over 57% of shares tendered, allowing JNJ to proceed with a merger and take ABIOMED private. The total consideration included a cash payment of $380 per share plus a Contingent Value Right (CVR) for each share. The aggregate value of the acquisition, excluding fees, was approximately $17.1 billion, funded through a combination of cash on hand and short-term financing. The CVRs represent the potential for additional payments of up to $35 per share, contingent on the achievement of specific milestones related to net sales of ABIOMED's products and regulatory approvals. These milestones include targets for net sales exceeding $3.7 billion in a defined period, FDA approval for specific Impella product uses, and the achievement of Class I recommendations in clinical practice guidelines for the Impella product family in various cardiovascular conditions. JNJ has committed significant investment towards achieving some of these milestones.
JOHNSON & JOHNSON 8-K Report, Executive Changes (Dec 1, 2022)
Johnson & Johnson (JNJ) has announced a significant leadership transition via an 8-K filing on November 30, 2022. Effective upon the retirement of current Chairman Alex Gorsky from the Board of Directors in January 2023, Joaquin Duato, who is already serving as the Chief Executive Officer, will assume the role of Chairman of the Board. This move consolidates the CEO and Chairman positions under Mr. Duato, signaling a unified leadership direction for the company. Mr. Gorsky's departure from the Board in January 2023, after a brief transition, marks the end of his tenure and he will not stand for reelection. This transition is a key event for investors as it signifies a new chapter in JNJ's strategic leadership, with Mr. Duato now set to guide the company in both its operational and governance capacities. The accompanying press release, filed as an exhibit, provides further details on this development.
JOHNSON & JOHNSON 8-K Report, Material Agreement (Nov 1, 2022)
Johnson & Johnson (JNJ) announced on October 31, 2022, that it has entered into a definitive agreement to acquire ABIOMED, Inc. (ABMD) through a tender offer followed by a merger. The transaction is valued at $380.00 per ABIOMED share in cash, plus a non-tradeable contingent value right (CVR) that could provide up to an additional $35.00 per share. This acquisition is a significant move to bolster JNJ's medtech portfolio, specifically in the cardiovascular space with ABIOMED's leading heart pumps. The deal is subject to customary closing conditions, including antitrust approvals and the tender of at least 50% of ABIOMED's outstanding shares. The contingent value right introduces an element of future upside potential for ABIOMED shareholders based on specific sales and regulatory milestones, primarily related to ABIOMED's Impella heart pump technology. Investors should monitor regulatory approvals and the tender offer progress, as well as the potential impact of the CVRs on the ultimate acquisition price.
JOHNSON & JOHNSON 8-K Report, Financial Results (Oct 18, 2022)
Johnson & Johnson (JNJ) filed an 8-K on October 18, 2022, reporting its third-quarter financial results for the period ended October 2, 2022. The filing includes a press release and supplementary financial data detailing the company's performance. Investors should note that this report primarily serves to disseminate the previously announced Q3 2022 earnings, without introducing new operational or strategic developments beyond the financial outcomes themselves. The key takeaway for investors is the financial performance as detailed in the attached press release and supplementary sales data. While this 8-K does not contain forward-looking guidance or strategic shifts, it provides the official record of JNJ's sales and earnings for the quarter, which is crucial for evaluating the company's ongoing financial health and operational execution against market expectations.
JOHNSON & JOHNSON 8-K Report, Corporate Update (Sep 14, 2022)
Johnson & Johnson (JNJ) announced a significant capital allocation decision through its Board of Directors authorizing a new share repurchase program of up to $5 billion. This move signals management's confidence in the company's financial health and its commitment to returning value to shareholders. The program has no fixed expiration and allows for flexibility in execution, with repurchases potentially occurring on the open market or through private negotiations. Importantly, the company stated it does not anticipate incurring debt to fund these repurchases, indicating sufficient internal cash flow generation. In addition to the share buyback authorization, Johnson & Johnson reaffirmed its full-year financial guidance. The company maintains its outlook for adjusted operational sales growth of 7% (projected at $97.8 billion) and adjusted operational earnings per share (EPS) growth of 9.2% (projected at $10.70). This reaffirmation, coupled with the significant share repurchase authorization, suggests a stable and positive outlook for JNJ's performance through the remainder of 2022.